Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty

Arthritis Care and Research

Volumn 69, Issue 12, 2017, Pages 1845-1854

  George, Michael D ^a   Baker, Joshua F ^b   Hsu, Jesse Yenchih ^a   Wu, Qufei ^a   Xie, Fenglong ^c   Chen, Lang ^c   Yun, Huifeng ^c   Curtis, Jeffrey R ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; INFLIXIMAB; ANTIRHEUMATIC AGENT;

AGE DISTRIBUTION; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIP ARTHROPLASTY; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; KNEE ARTHROPLASTY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PERIPROSTHETIC JOINT INFECTION; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; REVISION ARTHROPLASTY; RHEUMATOID ARTHRITIS; SEPTICEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ADVERSE DEVICE EFFECT; CHI SQUARE DISTRIBUTION; DEVICES; DRUG ADMINISTRATION; ELECTIVE SURGERY; HIP; HIP PROSTHESIS; HIP REPLACEMENT; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFECTION; KAPLAN MEIER METHOD; KNEE; KNEE PROSTHESIS; KNEE REPLACEMENT; MEDICARE; MICROBIOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; SURGERY; TIME FACTOR; UNITED STATES;

AGED; ANTIRHEUMATIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; ELECTIVE SURGICAL PROCEDURES; FEMALE; GLUCOCORTICOIDS; HIP JOINT; HIP PROSTHESIS; HUMANS; IMMUNOCOMPROMISED HOST; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; KNEE JOINT; KNEE PROSTHESIS; LOGISTIC MODELS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85032796496     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23209     Document Type: Article

References (45)

1. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125–33.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.
3. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1810–4.
4. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72:229–34.
5. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al. Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896–904.
6. Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689–95.
7. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1713–20.
8. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430–6.
9. Waterman M, Xu W, Dinani A, Steinhart AH, Croitoru K, Nguyen GC, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013;62:387–94.
10. Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramers-de Quervain IA. Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res (Hoboken) 2013;65:2032–40.
11. Abou Zahr Z, Spiegelman A, Cantu M, Ng B. Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs’ administrative database study. Rheumatol Int 2015;35:265–72.
12. Goodman SM, Menon I, Christos PJ, Smethurst R, Bykerk VP. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford) 2016;55:573–82.
13. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.
14. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Part II: safety. J Rheumatol 2012;39:1583–602.
15. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217–9.
16. Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum 2015;44:627–32.
17. Centers for Medicare & Medicaid Services. Brief summaries of Medicare & Medicaid. 2015. URL: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/SummaryMedicareMedicaid.html.
18. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011;20:1199–209.
19. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
20. Liu L, Allison JE, Herrinton LJ. Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization. Pharmacoepidemiol Drug Saf 2009;18:1086–93.
21. Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, et al. Diagnostic prevalence of ankylosing spondylitis using computerized health care data, 1996 to 2009: underrecognition in a US health care setting. Perm J 2016;20:4–10.
22. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoepidemiol Drug Saf 2013;22:842–9.
23. Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA, et al. Rates and outcomes of primary and revision total hip replacement in the United States Medicare population. J Bone Joint Surg Am 2003;85-A:27–32.
24. Katz JN, Barrett J, Mahomed NN, Baron JA, Wright RJ, Losina E. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am 2004;86-A:1909–16.
25. Mahomed NN, Barrett J, Katz JN, Baron JA, Wright J, Losina E. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am 2005;87:1222–8.
26. Katz JN, Losina E, Barrett J, Phillips CB, Mahomed NN, Lew RA, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am 2001;83-A:1622–9.
27. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754–64.
28. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop 2010;468:52–6.
29. Bozic KJ, Lau E, Kurtz S, Ong K, Rubash H, Vail TP, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg Am 2012;94:794–800.
30. Fry DE, Pine M, Locke D, Pine G. Prediction models of Medicare 90-day postdischarge deaths, readmissions, and costs in bowel operations. Am J Surg 2015;209:509–14.
31. Yokoe D, Onufrak F, Olsen M, Stevenson K, Khan Y, Hooper D. Multicenter evaluation of enhanced surgical site infection surveillance following total knee and hip arthroplasty [abstract]. International Conference on Healthcare-Associated Infections, Atlanta, Georgia, March 18–22, 2010. URL: https://shea.confex.com/shea/2010/webprogram/Paper1547.html.
32. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749–59.
33. U.S. Census Bureau. American community survey. URL: https://www.census.gov/programs-surveys/acs.
34. Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJ, Andrea H, et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 2010;48:166–74.
35. Feng P, Zhou XH, Zou QM, Fan MY, Li XS. Generalized propensity score for estimating the average treatment effect of multiple treatments. Stat Med 2012;31:681–97.
36. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388–414.
37. Austin PC, Schuster T. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study. Stat Methods Med Res 2016;25:2214–37.
38. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656–64.
39. Dixon W, Lunt M, Watson K, Hyrich K, Symmons D. Anti-TNF therapy and the risk of serious post-operative infection: results from the BSR biologics register (BSRBR). Ann Rheum Dis 2007;66 Suppl II:118.
40. Michaud K, Fehringer EV, Garvin K, O'Dell JR, Mikuls TR. Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. Arthritis Res Ther 2013;15:R195.
41. Gilson M, Gossec L, Mariette X, Gherissi D, Guyot MH, Berthelot JM, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther 2010;12:R145.
42. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J 2013;7:119–24.
43. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320–7.
44. Ferrante M, D'Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062–70.
45. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785–91.